Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about a scheduled Board Meeting to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. It references Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures related to board meetings. The document does not contain the financial results themselves but is an intimation or announcement of the upcoming board meeting where such results will be approved. The document length is short (2359 characters), and it serves as a notification rather than the actual financial report. Therefore, it fits the category of Regulatory Filings (RNS) as a general regulatory announcement and not an Interim/Quarterly Report (IR) or Earnings Release (ER).
2025-07-17 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Audit Report / Information Classification · 95% confidence The document is titled 'Reconciliation of Share Capital Audit Report' for the quarter ended June 30, 2025, prepared by a practicing Company Secretary. It is submitted under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The content includes detailed share capital structure, dematerialized shares, physical shares, and compliance officer details. It is a standalone audit report related to share capital reconciliation, not a full annual or quarterly financial report. The document length is about 7990 characters, which is sufficient to contain substantive data, not just an announcement. Therefore, this fits the category of an Audit Report / Information (AR) rather than a Regulatory Filing or Report Publication Announcement. Q1 2025
2025-07-14 English
Giving guarantees/indemnity/ becoming a surety for third party
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the issuance of a corporate guarantee by Senores Pharmaceuticals Limited for credit facilities availed by its material subsidiary, Havix Group Inc. The subject and content clearly indicate it is an intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The document provides details about the guarantee, its amount, terms, and impact on the company. It is a regulatory announcement about a corporate guarantee related to financing activities, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees.
2025-07-10 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the acquisition of equity shares in a subsidiary company, Havix Group Inc. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content details the acquisition of 6730 shares (2.97%) to increase the company's holding in the subsidiary from 70.07% to 73.04%. It includes specifics such as the share purchase agreement, consideration, regulatory approvals, and background of the acquired entity. This is a clear update on a capital transaction involving share acquisition, not a full financial report, earnings release, or management discussion. It is not a report publication announcement or certification. Therefore, the document fits best under Capital/Financing Update (CAP) as it informs about a financing/capital structure change through acquisition of shares in a subsidiary.
2025-07-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2025. It is a confirmation certificate from the Registrar and Share Transfer Agent regarding dematerialisation of securities and related compliance. The document is addressed to stock exchanges and is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 3537 characters, which is relatively short and primarily a certification letter. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certifications that do not fit other specific categories.
2025-07-10 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the closure of the trading window for insiders ahead of the announcement of unaudited quarterly financial results. It references compliance with insider trading regulations and specifies the period during which trading is prohibited. There is no actual financial data or results presented, nor is there a report attached or published. The document is an announcement related to trading restrictions in anticipation of a financial report, not the report itself. Therefore, it does not fit categories like Interim/Quarterly Report (IR) or Earnings Release (ER). It is a regulatory compliance announcement related to insider trading rules, which fits best under Regulatory Filings (RNS). The document length is short (2091 characters), and it is not a report publication announcement (RPA) since it does not mention report availability. Hence, the classification is Regulatory Filings (RNS) with high confidence.
2025-06-25 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.